Ceramide as a risk factor of nonalcoholic fatty liver disease

##plugins.themes.bootstrap3.article.sidebar##

PDF (Русский)
Published: Aug 6, 2018
DOI: https://doi.org/10.30841/2307-5112.3.2018.146737
Keywords:
nonalcoholic fatty liver disease, ceramide, apoptosis, insulin resistance,

##plugins.themes.bootstrap3.article.main##

Л. Л. Павловський
Bogomolets National Medical University, Ukraine
В. В. Чернявський
Bogomolets National Medical University, Ukraine

Abstract

At present, one of the factors of the pathogenesis of nonalcoholic fatty liver disease, which deserve particular attention, is the accumulation of specific lipid subspecies in the liver – ceramides. This article shows what the ceramides are, how they are formed, and how they influence on apoptosis and development of insulin.

##plugins.themes.bootstrap3.article.details##

How to Cite
Павловський, Л. Л., & Чернявський, В. В. (2018). Ceramide as a risk factor of nonalcoholic fatty liver disease. Family Medicine, (3), 81–84. https://doi.org/10.30841/2307-5112.3.2018.146737
Issue
No. 3 (2018)
Section
Gastroenterology
Copyright (c) 2020 Л. Л. Павловський, В. В. Чернявський

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

Л. Л. Павловський, Bogomolets National Medical University

Leonid L. Pavlovskyi,

Department of Internal Medicine № 1

В. В. Чернявський, Bogomolets National Medical University

Volodymyr V. Chernyavskyi,

Department of Internal Medicine № 1

References

Vernon, G., Baranova, A., and Younossi, Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34: 274–85https://doi.org/10.1111/j.1365-2036.2011.04724.x

Angulo P. GI Epidemiology: nonalcoholic fatty liver disease. P. Angulo // Alimentary Pharmacology & Therapeutics. – 2007. – V. 25. – P.883–889. https://doi.org/10.1111/j.1365-2036.2007.03246.x

Oh M.K. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. M.K.Oh, J.Winn, F. Poordad // Ailment Pharmacol Ther. – 2008. – Vol. 28. – P. 503–522. https://doi.org/10.1111/j.1365-2036.2008.03752.x

Exendin-4 improves steatohepatitis by increasing Sirt1 expression in highfat diet-induced obese C57BL/6J mice. J Lee, SW Hong, SW Chae et al. // PloS One. – 2012. –Vol.7, N2. – P.63–72. https://doi.org/10.1371/journal.pone.0031394

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. K Promrat, DE Kleiner, HM Niemeier, E Jackvony et al. // Hepatology. – 2010. – V51. – P121–129 https://doi.org/10.1002/hep.23276

Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease in type 2 diabetic patients. Diabetes Care 2007; 30:1212–1218. https://doi.org/10.2337/dc06-2247

Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Baijal R, Lala S, Chaudhary D, Deshpande A. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol. 2007; 6(3):161–163. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, ho K, Sung IK. PDF

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–285 http://dx.doi.org/10.1111/j.1365-2036.2011.04724.x

EASL–EASD–EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease 2016 https://doi.org/10.1016/j.jhep.2015.11.004

Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13:511–31. https://doi.org/10.1016/j.cld.2009.07.005

Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014; 15:8591–638. https://doi.org/10.3390/ijms15058591

Bugianesi E, Moscatiello S, Ciaravella MF, et al. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16:1941–51. https://doi.org/10.2174/138161210791208875

Cusi K. Role of insulin resistance and lipotoxicity in nonalcoholic steatohepatitis. Clin Liver Dis 2009; 13:545–63. https://doi.org/10.1016/j.cld.2009.07.009

Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016, Apr;15(4):249–74. https://doi.org/10.1038/nrd.2015.3

Castro, B. M., Prieto, M. & Silva, L.C. Ceramide: a simple sphingolipid with unique biophysical properties. Prog. Lipid Res. 54, 53–67 (2014). https://doi.org/10.1016/j.plipres.2014.01.004

Gault, C.R. et al. (2010) An overview of sphingolipid metabolism: from synthesis to breakdown. Adv. Exp. Med. Biol. 688, 1–23 Full text

Frangioudakis, G. et al. (2010) Saturated-and n-6 polyunsaturated-fat diets each induce ceramide accumulation in mouse skeletal muscle: reversal and improvement of glucose tolerance by lipid metabolism inhibitors. Endocrinology 151, 4187–4196 https://doi.org/10.1210/en.2010-0250

Chocian, G. et al. (2010) High fat diet induces ceramide and sphingomyelin formation in rat’s liver nuclei. Mol. Cell. Biochem. 340, 125–131 https://doi.org/10.1007/s11010-010-0409-6

Nikolova-Karakashian, M.N. and Rozenova, K.A. (2010) Ceramide in stress response. Adv. Exp. Med. Biol. 688, 86–108 https://doi.org/10.1007/978-1-4419-6741-1_6

Holland, W.L. and Summers, S.A. (2008) Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 29, 381–402 https://doi.org/10.1210/er.2007-0025

Clarke, C.J. et al. (2006) The extended family of neutral sphingomyelinases. Biochemistry 45, 11247–11256 https://doi.org/10.1021/bi061307z

Mari, M. and Fernandez-Checa, J.C. (2007) Sphingolipid signalling and liver diseases. Liver Int. 27, 440–450 https://doi.org/10.1111/j.1478-3231.2007.01475.x

Summers, S.A. (2006) Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45, 42–72 https://doi.org/10.1016/j.plipres.2005.11.002

Semple, R.K. et al. (2009) Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J. Clin. Invest. 119, 315–322 https://doi.org/10.1172/JCI37432

JeBailey, L. et al. (2007) Ceramide and oxidant-induced insulin resistance involve loss of insulin-dependent Racactivation and actin remodeling in muscle cells. Diabetes 56, 394–403 https://doi.org/10.2337/db06-0823

Ribaux, P.G. and Iynedjian, P.B. (2003) Analysis of the role of protein kinase B (cAKT) in insulin-dependent induction of glucokinase and sterol regulatory element-binding protein 1 (SREBP1) mRNAs in hepatocytes. Biochem. J. 376, 697–705 https://doi.org/10.1042/BJ20031287

Colombini, M. (2010) Ceramide channels and their role in mitochondriamediated apoptosis. Biochim. Biophys. Acta 1797, 1239–1244 https://doi.org/10.1016/j.bbabio.2010.01.021

Mari, M. et al. (2008) Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kappaB activation. Gastroenterology 134, 1507–1520 https://doi.org/10.1053/j.gastro.2008.01.073

Edelmann, B. et al. (2011) Caspase-8 and caspase-7 sequentially mediate proteolytic activation of acid sphingomyelinase in TNF-R1 receptosomes. EMBO J. 30, 379–394 https://doi.org/10.1038/emboj.2010.326

Mangesh Pagadala, Takhar Kasumov,Arthur J. McCullough,Nizar N. Zein,and John P. Kirwan Role of Ceramides in Nonalcoholic Fatty Liver Disease Trends Endocrinol Metab. 2012 Aug; 23(8): 365–371. https://dx.doi.org/10.1016%2Fj.tem.2012.04.005